Replimune Group Stock Price, News & Analysis

Replimune Group, Inc. (Nasdaq: REPL) is a clinical stage biotechnology company focused on the research and development of oncolytic immunotherapies for the treatment of cancer. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune is developing product candidates that use a proprietary RPx platform based on a potent herpes simplex virus type 1 (HSV‑1) backbone. According to the company, this platform is designed to maximize immunogenic cell death and induce a systemic anti‑tumor immune response against solid tumors.

The RPx platform is intended to ignite local activity at the tumor site through direct selective virus‑mediated killing of tumor cells, resulting in the release of tumor‑derived antigens and alteration of the tumor microenvironment. This local activity is expected to then activate a strong and durable systemic immune response. Replimune states that its RPx product candidates are expected to be synergistic with many established and experimental cancer treatment modalities, and are being developed both as monotherapies and in combination with other treatments.

Core technology and RPx platform

Replimune’s RPx platform is based on a proprietary, engineered strain of HSV‑1 with added payloads intended to enhance anti‑tumor immunity. The company describes the platform as designed to maximize immunogenic cell death and support the induction of systemic anti‑tumor immune responses. The dual local and systemic activity is characterized by:

• Direct, selective killing of tumor cells by the modified virus.
• Release of tumor‑derived antigens into the tumor microenvironment.
• Alteration of the tumor microenvironment to support immune activation.
• Activation of a broader systemic immune response against cancer.

This approach is positioned by Replimune as a way to address tumors that have proven resistant to existing immunotherapies, including immune checkpoint inhibitors.

Lead product candidate: RP1 (vusolimogene oderparepvec)

RP1, also known as vusolimogene oderparepvec, is Replimune’s lead product candidate. RP1 is based on a proprietary strain of HSV‑1 engineered and genetically armed with a fusogenic protein (GALV‑GP R‑) and GM‑CSF. According to the company, RP1 is intended to:

• Maximize tumor‑killing potency.
• Increase the immunogenicity of tumor cell death.
• Promote activation of a systemic anti‑tumor immune response.

RP1 is being evaluated in combination with the PD‑1 inhibitor nivolumab in advanced melanoma and in various non‑melanoma skin cancers. The IGNYTE clinical trial program includes a phase 2 cohort in advanced cutaneous melanoma that has progressed on anti‑PD‑1‑based therapy, and additional cohorts in non‑melanoma skin cancers such as Merkel cell carcinoma, basal cell carcinoma, angiosarcoma and cutaneous squamous cell carcinoma, including patients with prior anti‑PD‑1 exposure. RP1 is also being studied as monotherapy in cutaneous squamous cell carcinoma patients following organ transplant in the ARTACUS phase 2 trial.

Replimune has submitted a Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on an anti‑PD‑1‑containing regimen. The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) in July 2025, indicating that the IGNYTE trial was not considered an adequate and well‑controlled clinical investigation providing substantial evidence of effectiveness. The company subsequently held a Type A meeting with the FDA and later announced that the FDA accepted a BLA resubmission for RP1 in combination with nivolumab for advanced melanoma, with a Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026, based on a Class II resubmission timeline.

Additional product candidate: RP2

RP2 is another oncolytic immunotherapy candidate based on a proprietary HSV‑1 strain engineered and genetically armed with the same fusogenic protein (GALV‑GP R‑) and GM‑CSF as RP1. RP2 additionally expresses an anti‑CTLA‑4 antibody‑like molecule. Replimune states that RP2 is intended to provide targeted and potent delivery of these proteins to sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic immune‑based efficacy on tumors and limiting off‑target toxicity.

RP2 is being evaluated in multiple clinical settings, including:

• A registration‑directed phase 2/3 trial called REVEAL in metastatic uveal melanoma, where RP2 in combination with nivolumab is being compared to ipilimumab plus nivolumab in immune checkpoint inhibitor‑naïve patients.
• A phase 2 trial of RP2 in combination with atezolizumab and bevacizumab in hepatocellular carcinoma that has progressed on prior PD‑1/PD‑L1 therapy, conducted under a collaboration and supply agreement with Roche.
• A cohort evaluating RP2 in patients with biliary tract cancer, where RP2 is combined with durvalumab.

Clinical development focus

Replimune’s clinical programs are centered on difficult‑to‑treat cancers where there is significant unmet medical need, particularly in patients who have progressed on or are ineligible for existing immunotherapies. Key areas of focus described in company communications include:

• Advanced melanoma following progression on anti‑PD‑1‑based therapy, including acral melanoma, a rare and aggressive subtype of cutaneous melanoma.
• Non‑melanoma skin cancers, such as Merkel cell carcinoma, basal cell carcinoma, angiosarcoma and cutaneous squamous cell carcinoma, in both anti‑PD‑1‑naïve and anti‑PD‑1‑failed settings.
• Skin cancer in organ transplant recipients, where RP1 is being evaluated as monotherapy in cutaneous squamous cell carcinoma patients following organ transplant in the ARTACUS trial.
• Metastatic uveal melanoma, through the REVEAL trial of RP2 in combination with nivolumab.
• Hepatocellular carcinoma and biliary tract cancer, where RP2 is studied in combination with other immunotherapy and targeted agents.

The global phase 3 trial IGNYTE‑3 is assessing RP1 in combination with nivolumab versus physician’s choice of treatment in patients with advanced melanoma who have progressed on anti‑PD‑1 and anti‑CTLA‑4 therapies or are ineligible for anti‑CTLA‑4 treatment. This trial is designed with overall survival as the primary endpoint and progression‑free survival and overall response rate as key secondary endpoints.

Regulatory and corporate context

Replimune’s interactions with the FDA, including the CRL for the RP1 BLA and subsequent Type A meeting and resubmission, are central to the company’s regulatory pathway. The company has highlighted feedback from the melanoma community, including patients and physicians, regarding the unmet need in advanced melanoma and the clinical data generated with RP1 in the IGNYTE trial. Through its public disclosures and SEC filings, Replimune has discussed its efforts to work with the FDA on pathways for potential approval and confirmatory trial design.

Replimune’s shares trade on the Nasdaq Global Select Market under the symbol REPL. The company files periodic reports, proxy statements and current reports on Form 8‑K with the U.S. Securities and Exchange Commission (SEC), which provide additional detail on its clinical programs, financial position, governance and risk factors.

Geographic footprint and operations

According to available descriptions, Replimune operates in the United States and the United Kingdom, with the majority of its revenue reported as coming from the United States. The company’s principal executive offices are located in Woburn, Massachusetts. Its activities are concentrated in the professional, scientific and technical services sector, within the biotechnology research and development industry.

Investment perspective

As a clinical stage biotechnology company, Replimune’s value proposition is closely tied to the progress and outcomes of its clinical trials, regulatory reviews and potential future approvals of its product candidates. Investors and analysts often monitor milestones such as BLA submissions and resubmissions, FDA feedback, PDUFA dates, clinical trial readouts, and collaborations with other pharmaceutical companies. Replimune’s SEC filings, including Forms 10‑K, 10‑Q and 8‑K, outline the risks and uncertainties associated with its limited operating history, clinical development, regulatory processes and broader macroeconomic and industry factors.

Frequently asked questions about Replimune Group, Inc. (REPL)

• What does Replimune Group, Inc. do?
  

  Replimune Group, Inc. is a clinical stage biotechnology company developing oncolytic immunotherapies for the treatment of cancer. Its programs are based on a proprietary HSV‑1‑derived RPx platform designed to maximize immunogenic cell death and induce systemic anti‑tumor immune responses.

• What is the RPx platform?
  

  The RPx platform is Replimune’s proprietary technology based on a potent HSV‑1 backbone engineered with additional payloads. It is intended to drive direct virus‑mediated killing of tumor cells, release tumor‑derived antigens and alter the tumor microenvironment, which together are expected to trigger a strong and durable systemic immune response.

• What is RP1?
  

  RP1 (vusolimogene oderparepvec) is Replimune’s lead product candidate. It is an HSV‑1‑based oncolytic immunotherapy genetically armed with a fusogenic protein (GALV‑GP R‑) and GM‑CSF. RP1 is being evaluated in advanced melanoma and non‑melanoma skin cancers, often in combination with the PD‑1 inhibitor nivolumab.

• What is RP2?
  

  RP2 is another HSV‑1‑based oncolytic immunotherapy candidate engineered with GALV‑GP R‑ and GM‑CSF and additionally expressing an anti‑CTLA‑4 antibody‑like molecule. It is intended to deliver these proteins directly to tumors and draining lymph nodes to enhance immune responses while limiting off‑target effects, and is being studied in metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.

• Which cancers are being targeted in Replimune’s clinical trials?
  

  Replimune’s disclosed clinical programs focus on advanced melanoma (including acral melanoma) that has progressed on anti‑PD‑1‑based therapy, various non‑melanoma skin cancers such as Merkel cell carcinoma, basal cell carcinoma, angiosarcoma and cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma in organ transplant recipients, metastatic uveal melanoma, hepatocellular carcinoma and biliary tract cancer.

• What is the status of RP1’s regulatory review in advanced melanoma?
  

  The FDA issued a Complete Response Letter in July 2025 for the BLA for RP1 in combination with nivolumab in advanced melanoma, citing concerns about the adequacy and interpretability of the IGNYTE trial. Following a Type A meeting, Replimune resubmitted the BLA, and the FDA accepted the resubmission with a PDUFA target action date of April 10, 2026, based on a Class II resubmission timeline.

• On which exchange does Replimune trade and what is its ticker symbol?
  

  Replimune Group, Inc. trades on the Nasdaq Global Select Market under the ticker symbol REPL.

• When was Replimune founded and where is it headquartered?
  

  Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

• How does Replimune describe the potential use of its product candidates with other therapies?
  

  The company states that its RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, and that they have the versatility to be developed alone or in combination with a variety of other treatment options.

• Where can investors find more detailed information about Replimune?
  

  Investors can review Replimune’s filings with the U.S. Securities and Exchange Commission, including annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K and proxy statements, which provide detailed information on the company’s clinical programs, financials, governance and risk factors.